Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.53B | 52.94B | 46.58B | 44.25B | 37.11B | 29.27B |
| Gross Profit | 44.00B | 39.70B | 34.45B | 28.04B | 22.60B | 21.66B |
| EBITDA | 19.75B | 14.86B | 13.20B | 8.63B | 4.59B | 8.04B |
| Net Income | 9.51B | 6.89B | 6.06B | 3.28B | 109.85M | 3.39B |
Balance Sheet | ||||||
| Total Assets | 114.46B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B |
| Cash, Cash Equivalents and Short-Term Investments | 8.18B | 5.65B | 5.91B | 6.24B | 6.37B | 7.95B |
| Total Debt | 32.66B | 30.11B | 28.41B | 29.14B | 30.69B | 20.38B |
| Total Liabilities | 68.48B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B |
| Stockholders Equity | 45.89B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
Cash Flow | ||||||
| Free Cash Flow | 11.15B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B |
| Operating Cash Flow | 15.14B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B |
| Investing Cash Flow | -6.54B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M |
| Financing Cash Flow | -4.93B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £211.95B | 29.44 | 22.34% | 1.54% | 10.20% | 40.57% | |
77 Outperform | £73.51B | 13.47 | 36.44% | 3.30% | 2.73% | 119.38% | |
75 Outperform | £3.33B | 11.67 | 15.66% | 4.17% | 3.73% | 27.13% | |
73 Outperform | £33.29B | 22.24 | 9.35% | 1.51% | -2.12% | 42.10% | |
70 Outperform | £10.47B | 28.40 | 9.30% | 2.34% | 2.51% | 56.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AstraZeneca Corporate Events
AstraZeneca PLC announced that as of November 30, 2025, its issued share capital with voting rights consists of 1,550,725,869 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s rules, which could impact shareholder engagement and transparency in the company’s governance.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as the first perioperative immunotherapy for early-stage gastric and gastroesophageal junction cancers, based on the MATTERHORN Phase III trial results. This approval, which follows a Priority Review by the FDA, marks a significant advancement in the treatment of these cancers, offering a new standard of care with a notable survival benefit. The Imfinzi regimen, combined with FLOT chemotherapy, demonstrated a 29% reduction in disease progression risk and a 22% reduction in death risk compared to chemotherapy alone, establishing a new clinical paradigm and providing renewed hope for patients.
AstraZeneca has announced a $2 billion investment to expand its manufacturing operations in Maryland, which will support 2,600 jobs and boost economic growth. This expansion includes enhancing its biologics manufacturing facility in Frederick and building a new state-of-the-art facility in Gaithersburg, both of which will be operational by 2029. The move is part of AstraZeneca’s broader $50 billion commitment to medicines manufacturing and R&D, aimed at strengthening the US medicine supply chain and accelerating access to transformative therapies.
AstraZeneca’s Koselugo (selumetinib) has been approved by the US FDA for treating adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), based on positive results from the KOMET Phase III trial. This approval marks a significant advancement in treatment options for adults with NF1, building on Koselugo’s established use in pediatric patients, and is expected to enhance AstraZeneca’s position in the rare disease market while providing continuity of care for NF1 patients.
AstraZeneca announced a transaction involving the sale of 15,000 American Depositary Shares by Aradhana Sarin, the company’s Executive Director and Chief Financial Officer, at a price of $88.6345 per share. This transaction, disclosed in accordance with EU Market Abuse Regulation, may have implications for stakeholders as it reflects executive-level financial decisions within the company.
AstraZeneca announced that its CEO, Pascal Soriot, has gifted 136,537 ordinary shares of the company to family members without any financial consideration. This transaction was conducted outside a trading venue and aligns with the regulatory requirements of the EU Market Abuse Regulation, reflecting transparency in executive shareholding activities.
AstraZeneca reported strong financial performance for the first nine months of 2025, with total revenue increasing by 11% to $43.2 billion, driven by growth in all therapy areas, especially oncology. The company achieved 16 positive Phase III trial readouts and 31 major approvals, reinforcing its pipeline strength. AstraZeneca is also expanding its operations in the US, including a $4.5 billion manufacturing facility in Virginia, and has reached a historic agreement with the US government to lower drug costs, which is expected to enhance its market positioning and stakeholder relations.
AstraZeneca announced that its shareholders have approved a resolution to adopt new articles of association, facilitating the harmonization of its equity listing structure across London, Stockholm, and New York. This move is expected to provide AstraZeneca with greater flexibility to access a broader pool of capital, particularly in the US, and reflects strong shareholder support. The new structure is anticipated to enhance AstraZeneca’s market presence and investment opportunities as it continues to expand in its growing markets.
AstraZeneca has announced that as of 31 October 2025, its issued share capital with voting rights consists of 1,550,712,906 ordinary shares, with none held in Treasury. This figure is crucial for shareholders to determine their notification obligations under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and regulatory compliance.
AstraZeneca’s Koselugo (selumetinib) has been approved in the EU for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1), based on the KOMET Phase III trial results. This approval marks a significant advancement in the treatment landscape for NF1, extending the benefits of Koselugo from pediatric to adult patients, and highlights AstraZeneca’s commitment to addressing unmet needs in the rare disease community.
AstraZeneca, in collaboration with Amgen, announced the European Union approval of Tezspire (tezepelumab) for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults who have not responded to standard therapies. This approval, based on the successful results of the WAYPOINT Phase III trial, marks a significant advancement in treatment options for CRSwNP, potentially reducing the need for surgery and systemic corticosteroids, and reinforcing AstraZeneca’s position in addressing epithelial-driven inflammation.
AstraZeneca and Amgen’s Tezspire has been approved by the US FDA for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), expanding its indications beyond severe asthma. This approval, based on the successful results of the WAYPOINT Phase III trial, positions Tezspire as a novel treatment option that significantly reduces the need for surgeries and systemic corticosteroid use, offering relief to millions affected by this condition. The approval is expected to enhance AstraZeneca’s market position in respiratory and immunology, reflecting its commitment to transforming patient care in chronic respiratory and immune-mediated diseases.
AstraZeneca’s Saphnelo (anifrolumab) has been recommended for approval in the EU for self-administration via a pre-filled pen for adult patients with systemic lupus erythematosus (SLE). This recommendation by the CHMP is based on the TULIP-SC Phase III trial results, which demonstrated a significant reduction in disease activity. The approval could enhance patient access to Saphnelo, offering a convenient once-weekly option that aligns with updated treatment guidelines emphasizing reduced steroid use. This development positions AstraZeneca to further expand its presence in the autoimmune disease treatment market, potentially benefiting stakeholders by addressing unmet needs in SLE management.
AstraZeneca has announced a historic agreement with the US Government to lower prescription medicine costs for American patients, aligning prices with those in wealthy countries. This agreement includes a $50 billion investment in US manufacturing and R&D, supporting domestic sourcing and innovation, and aims to generate $80 billion in revenue by 2030. The initiative also involves AstraZeneca’s participation in the TrumpRx.gov platform for discounted direct-to-consumer sales and a delay in Section 232 tariffs, enhancing the company’s US operations and economic contributions.
AstraZeneca announced that its drug, baxdrostat, met the primary endpoint in the Bax24 Phase III trial, showing a significant reduction in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension. This breakthrough suggests a potential shift in treatment approaches for patients with uncontrolled hypertension, as baxdrostat offers a durable, once-daily regimen that could improve blood pressure management and reduce cardiovascular risks. The company plans to advance regulatory filings and expand baxdrostat’s use across other conditions where aldosterone plays a critical role, such as primary aldosteronism and chronic kidney disease.
AstraZeneca and Daiichi Sankyo announced significant results from the TROPION-Breast02 Phase III trial, where their drug Datroway showed a statistically significant improvement in overall and progression-free survival for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy. This breakthrough positions Datroway as a potential new standard of care, offering hope for patients with limited treatment options and potentially impacting AstraZeneca’s market position in oncology.
AstraZeneca has announced that as of September 30, 2025, its issued share capital with voting rights consists of 1,550,701,945 ordinary shares, with no shares held in Treasury. This information is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca, in collaboration with Daiichi Sankyo, announced positive results from the DESTINY-Breast05 Phase III trial, showcasing Enhertu’s significant improvement in invasive disease-free survival for patients with high-risk HER2-positive early breast cancer compared to T-DM1. These findings, along with previous results from the DESTINY-Breast11 trial, reinforce Enhertu’s potential as a foundational treatment option in curative-intent settings, potentially altering the treatment landscape for HER2-positive early breast cancer and offering new hope for patients at high risk of disease recurrence.
AstraZeneca has announced plans to harmonize its share listing structure across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. This move involves a direct listing of AstraZeneca shares on the NYSE, replacing the existing US ADRs on Nasdaq, to create a global listing for global investors. The company aims to broaden its investor base and enhance its access to capital markets, particularly in the US, which hosts the largest and most liquid public markets. Despite these changes, AstraZeneca will remain headquartered and tax resident in the UK, continuing its inclusion in the FTSE 100 and OMX Stockholm 30 indices, and adhering to UK governance standards. This strategic move is expected to support AstraZeneca’s long-term growth by reaching a broader mix of global investors.
AstraZeneca announced that Karen Knudsen, a Non-Executive Director, acquired 9 American Depositary Shares in the company through the reinvestment of the first interim dividend for the year ending December 2025. This transaction highlights the ongoing engagement of AstraZeneca’s leadership in the company’s financial activities, potentially reinforcing investor confidence and reflecting a positive outlook on the company’s future performance.
AstraZeneca’s Koselugo (selumetinib), an oral MEK inhibitor, has been recommended for approval by the CHMP in the European Union for treating symptomatic, inoperable plexiform neurofibromas in adults with neurofibromatosis type 1. This recommendation is based on the KOMET Phase III trial, which demonstrated a 20% objective response rate in tumor size reduction, highlighting the urgent need for targeted treatments in this patient population. The approval would extend Koselugo’s reach, building on its established use in pediatric patients and its recent approval in Japan and other countries, potentially offering a new treatment option for adults and enhancing AstraZeneca’s position in the rare disease market.
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval by the European Medicines Agency’s CHMP for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. This recommendation is based on the successful results of the WAYPOINT Phase III trial, which demonstrated significant reductions in nasal polyp severity and nasal congestion, along with a near-complete elimination of the need for surgery and reduced corticosteroid use. If approved, Tezspire will offer a new treatment option for CRSwNP, addressing the unmet needs of patients who do not find relief with current therapies. This development strengthens AstraZeneca’s position in respiratory care and highlights its commitment to transforming treatments for chronic and challenging conditions.
AstraZeneca announced positive interim results from the Phase III TULIP-SC trial, demonstrating that subcutaneous administration of Saphnelo significantly reduces disease activity in patients with systemic lupus erythematosus (SLE). The trial’s success supports the efficacy and safety of Saphnelo, potentially expanding its accessibility to more patients and aligning with updated clinical guidelines that emphasize remission and reduced corticosteroid use. The results are under regulatory review and will be presented at the upcoming American College of Rheumatology meeting.
AstraZeneca announced that its RESOLUTE Phase III trial for Fasenra (benralizumab) in treating chronic obstructive pulmonary disease (COPD) did not meet the primary endpoint of statistical significance, despite showing numerical improvement. The trial’s safety and tolerability profile were consistent with known data, and the company plans to analyze the full data set for further insights. Fasenra is already approved for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in multiple countries, and the results of this trial may impact its future applications and regulatory reviews.